Paper24470592
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Bhagwat N and 13 others. Blood, 2014. Cited by 97 papers, by iCite.
Cite this record
ConductScience Library. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Papers, record 24470592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24470592
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Genetic Therapy | Major topic |
| Janus Kinase 2 | Major topic |
| Molecular Targeted Therapy | Major topic |
| Myeloproliferative Disorders | Major topic |
| Amino Acid Substitution | |
| Animals | |
| Bone Marrow Neoplasms | |
| Cell Transformation, Neoplastic | |
| Combined Modality Therapy | |
| Gene Deletion | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Mice, Transgenic | |
| Receptors, Thrombopoietin | |
| Treatment Outcome |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| UL1 RR024996 | NCRR NIH HHS | United States | UL1RR024996 | PubMed and NIH | NIH RePORTER |
| R01 CA155226 | NCI NIH HHS | United States | R01CA155226 | PubMed and NIH | NIH RePORTER |
| R01 CA169784 | NCI NIH HHS | United States | R01CA169784 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| P01 CA186866 | NCI NIH HHS | United States | P01CA186866 | PubMed and NIH | NIH RePORTER |
| R01 CA172546 | NCI NIH HHS | United States | R01CA172546 | PubMed and NIH | NIH RePORTER |
| R01 CA151949 | NCI NIH HHS | United States | R01CA151949 | PubMed and NIH | NIH RePORTER |
| 1R01CA151949-01 | NCI NIH HHS | United States | R01CA151949 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 24677402 | Increasing therapeutic efficacy in MPN. | https://conductscience.org/library/papers/24677402 |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16834459 | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. | PLoS Med | 2006 | https://conductscience.org/library/papers/16834459 | PubMed |
| 2 | 15793561 | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. | Nature | 2005 | https://conductscience.org/library/papers/15793561 | PubMed |
| 3 | 21926964 | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. | Leukemia | 2012 | https://conductscience.org/library/papers/21926964 | PubMed |
| 4 | 20852385 | HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20852385 | PubMed |
| 5 | 9590173 | Jak2 is essential for signaling through a variety of cytokine receptors. | Cell | 1998 | https://conductscience.org/library/papers/9590173 | PubMed |
| 6 | 22684457 | Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. | Cancer Discov | 2012 | https://conductscience.org/library/papers/22684457 | PubMed |
| 7 | 15837627 | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. | Cancer Cell | 2005 | https://conductscience.org/library/papers/15837627 | PubMed |
| 8 | 21946277 | Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. | Nat Chem Biol | 2011 | https://conductscience.org/library/papers/21946277 | PubMed |
| 9 | 15737014 | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. | PLoS Med | 2005 | https://conductscience.org/library/papers/15737014 | PubMed |
| 10 | 20541703 | Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20541703 | PubMed |
| 11 | 15354294 | Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. | Genesis | 2004 | https://conductscience.org/library/papers/15354294 | PubMed |
| 12 | 11423618 | Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. | Science | 2001 | https://conductscience.org/library/papers/11423618 | PubMed |
| 13 | 15781101 | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. | Lancet | 2005 | https://conductscience.org/library/papers/15781101 | PubMed |
| 14 | 22916261 | Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. | PLoS One | 2012 | https://conductscience.org/library/papers/22916261 | PubMed |
| 15 | 22820254 | Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. | Nature | 2012 | https://conductscience.org/library/papers/22820254 | PubMed |
| 16 | 22375971 | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22375971 | PubMed |
| 17 | 16392823 | Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. | J Med Chem | 2006 | https://conductscience.org/library/papers/16392823 | PubMed |
| 18 | 22504184 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. | Nature | 2012 | https://conductscience.org/library/papers/22504184 | PubMed |
| 19 | 17267906 | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17267906 | PubMed |
| 20 | 20154217 | Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. | Blood | 2010 | https://conductscience.org/library/papers/20154217 | PubMed |
Cited by73
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 97 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41629621 | JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms. | Leukemia | 2026 | https://conductscience.org/library/papers/41629621 | PubMed |
| 41507381 | Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia. | Leukemia | 2026 | https://conductscience.org/library/papers/41507381 | PubMed |
| 39104388 | Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39104388 | PubMed |
| 39006945 | Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer. | Mol Ther Oncol | 2024 | https://conductscience.org/library/papers/39006945 | PubMed |
| 38230747 | Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38230747 | PubMed |
| 38177095 | Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/38177095 | PubMed |
| 37992313 | Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/37992313 | PubMed |
| 37771602 | Recent advances in therapies for primary myelofibrosis. | Fac Rev | 2023 | https://conductscience.org/library/papers/37771602 | PubMed |
| 37206258 | Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study. | EJHaem | 2023 | https://conductscience.org/library/papers/37206258 | PubMed |
| 36229595 | JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL. | Leukemia | 2022 | https://conductscience.org/library/papers/36229595 | PubMed |
| 36044173 | Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations. | Invest New Drugs | 2022 | https://conductscience.org/library/papers/36044173 | PubMed |
| 35903543 | JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. | Front Cell Dev Biol | 2022 | https://conductscience.org/library/papers/35903543 | PubMed |
| 35082276 | JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. | Blood Cancer J | 2022 | https://conductscience.org/library/papers/35082276 | PubMed |
| 34775887 | Novel strategies for challenging scenarios encountered in managing myelofibrosis. | Leuk Lymphoma | 2022 | https://conductscience.org/library/papers/34775887 | PubMed |
| 34110416 | Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. | Blood | 2021 | https://conductscience.org/library/papers/34110416 | PubMed |
| 34023895 | LigAdvisor: a versatile and user-friendly web-platform for drug design. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/34023895 | PubMed |
| 33882481 | Accelerated Phase of Myeloproliferative Neoplasms. | Acta Haematol | 2021 | https://conductscience.org/library/papers/33882481 | PubMed |
| 33782031 | Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33782031 | PubMed |
| 33472356 | Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. | Haematologica | 2021 | https://conductscience.org/library/papers/33472356 | PubMed |
| 33403355 | Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. | Hemasphere | 2021 | https://conductscience.org/library/papers/33403355 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HSP90AA1 | 3320 | PubTator's text mining | https://conductscience.org/library/genes/3320 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| MPL | 4352 | PubTator's text mining | https://conductscience.org/library/genes/4352 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24470592
GET https://conductscience.org/api/papers/v1/24470592/references?page=2